Physician profile
Ryan S Dunn
NPI 1881392439
$4,033.22
in general payments reported to CMS, 2019-2025
30 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $877 · 2024: $1,571 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $378.54 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $347.18 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $288.51 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.30 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $238.82 | 2023-2025 | |
| Axsome Therapeutics, INC. | $200.33 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $184.89 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $149.39 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $129.95 | 2023-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $125.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $79.41 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $71.03 | 2023-2025 | Azstarys |
| Exact Sciences Corporation | $69.85 | 2023-2025 | Cologuard Collection Kit |
| Pulmonx Corporation | $56.22 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $51.46 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $37.56 | 2023-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.40 | 2024 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $33.25 | 2023 | |
| Esperion Therapeutics, INC. | $32.96 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $32.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.93 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $21.48 | 2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $21.26 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $19.13 | 2024 | Trintellix |
| Dexcom, INC. | $18.04 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.77 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $16.25 | 2024 | Spravato |
| Ardelyx, INC. | $15.35 | 2024 | Ibsrela |
| Dynavax Technologies Corporation | $11.99 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.